Press releases

September 12, 2023

ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease

March 9, 2023

ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development

November 10, 2022

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

November 2, 2022

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

Reveal more

News and events

September 12, 2023

With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’  |  BioPharma Dive

September 12, 2023

Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma  |  Endpoints News

Reveal more

Publications and presentations

May 12, 2023

Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription  |  bioRxiv

January 11, 2023

ROME Therapeutics company presentation | 41st J.P. Morgan Healthcare Conference

Reveal more